YAP1 and neoplasm: Considering that Hippo-YAP/TAZ activation is established as a major factor of resistance to anti-tumor medications, traditional antitumor therapies combined with therapies targeting the Hippo pathway may be a trend in the coming years and ultimately benefit EC patients.